Exact Sciences (EXAS): Customer Relationships and Commercial Levers that Drive Value

Exact Sciences operates a vertically integrated cancer diagnostics business that monetizes primarily through laboratory testing services (Cologuard, Oncotype and other molecular tests), payer reimbursement, and selective distribution partnerships. The company sells tests directly to patients and through third-party channels while negotiating reimbursement contracts with large payers and developing international distribution for non-U.S. products. Key revenue drivers are payer coverage decisions and distribution scale; the commercial playbook is a hybrid of direct-to-patient lab services and channel partnerships.
Discover more coverage and relationship intelligence at https://nullexposure.com/.

How Exact makes money and why customers matter

Exact Sciences generates revenue when its lab tests are performed and reimbursed. Revenue collection is a function of patient billing, private payer contracts, and Medicare/Medicaid coverage, which directly links the company’s cash flow to payer contracting posture and regulatory reimbursement decisions. International revenue relies on exclusive distributor agreements for diagnostics like Oncotype, so global growth depends on partner performance and market access. The combination of high-margin molecular testing and exposure to concentrated payers makes customer relationships both commercial levers and key risk vectors.

Operating-model constraints as company-level signals

The company filing and investor communications reveal several structural characteristics that shape how Exact manages customers and risk:

• Contracting posture: Exact negotiates formal reimbursement contracts with large payers and relies on statutory coverage for Medicare, while patients are billed without formal reimbursement contracts. This creates mixed contracting dynamics—formal enterprise deals with payers and claims-driven billing for individuals.
• Concentration and criticality: Medicare represents a material portion of revenue, so CMS coverage decisions are critical to topline stability. Large enterprise payers (e.g., UnitedHealthcare) also account for meaningful percentages of revenue and receivables.
• Geographic maturity: The U.S. market is the most mature and revenue-centric for products like Cologuard, while Oncotype has an established international footprint supported by exclusive distributors—so international growth is dependent on distributor performance.
• Relationship roles and lifecycle: Exact acts as seller, service provider, and partner to distributors; many relationships are active and commercialized rather than exploratory.
• Segment focus: Revenue is concentrated in laboratory testing services, so customer risk is tightly coupled to testing demand and payer reimbursement.

These signals explain why payer contracting and channel execution receive outsized management attention in filings and calls.

Customer and payer map: what the filings and calls disclose

Below are the relationships identified in Exact Science’s public materials, each summarized with context and source.

• Freenome Holdings, Inc.
  Exact entered into an exclusive license agreement with Freenome, reflecting a product/technology partnership that supports Exact’s test portfolio and IP strategy. According to Exact’s FY2025 10‑K, the company documented an exclusive license arrangement with Freenome Holdings. (FY2025 10‑K)

• Centers for Medicare & Medicaid Services (CMS)
  Medicare and Medicaid coverage materially affect payments and billing terms; the 10‑K explains that payment terms depend on patients’ insurance benefits including CMS coverage decisions. Exact cites CMS as a central factor in reimbursement and revenue recognition. (FY2025 10‑K)

• Highmark
  Exact announced contracts with Highmark to provide Cologuard Plus coverage for members, expanding commercial access for that product. Management disclosed the Highmark agreement on the 2025 Q3 earnings call when discussing payer contract wins. (2025 Q3 earnings call)

• UnitedHealthcare
  UnitedHealthcare accounted for a double-digit share of revenue and accounts receivable in 2025, showing it is a major commercial payer for Exact’s tests. Exact’s FY2025 10‑K breaks down revenue and AR by major payers, with UnitedHealthcare representing 13% of 2025 revenue. (FY2025 10‑K)

• Humana
  Exact secured a contract with Humana that increases access to Cologuard Plus; management highlighted Humana as one of two top-ten payers that together represent roughly 40 million members. This was described on the 2025 Q2 earnings call. (2025 Q2 earnings call)

• Centene
  Exact signed a favorable agreement with Centene to expand Cologuard Plus access, contributing to a large-member expansion cited by management on the 2025 Q2 earnings call. (2025 Q2 earnings call)

• Aetna (CVS Health)
  Exact executed a contract with Aetna to include Cologuard Plus for plan members, announced alongside Highmark in the 2025 Q3 earnings call and positioned as part of the company’s payer expansion strategy. (2025 Q3 earnings call)

• Privia Health
  Exact collaborated with Privia Health on a colorectal cancer screening program that reported high screening rates, demonstrating a partnership model with provider groups and health systems to drive adoption and outcomes. A March 2026 press release covering the Privia-led program notes Exact was a supporting partner. (Biospace press release, Mar 2026)

• Abbott
  Abbott announced a proposal to acquire Exact Sciences in a transaction valued at up to $23 billion, a strategic outcome that would fold Exact’s diagnostics business into a larger medical device and diagnostics platform. The acquisition was reported by CNBC in November 2025. (CNBC, Nov 2025)

• Quest Diagnostics
  Exact entered an agreement with Quest Diagnostics to enable blood collection at approximately 7,000 patient access sites in the U.S., expanding specimen collection scale and patient convenience for blood‑based tests. This arrangement is disclosed in the FY2025 10‑K. (FY2025 10‑K)

These relationships collectively map Exact’s commercial architecture: payer contracts drive reimbursement and volume, provider and health system partnerships drive adoption, and distribution agreements extend geographic reach.

Explore connected relationship evidence and analytics at https://nullexposure.com/ to support your diligence.

What investors should focus on next

Three commercial realities determine upside and downside for Exact:

• Payer concentration risk: With Medicare and a handful of large payers accounting for a material share of revenue and receivables, coverage changes or reimbursement pressure will have immediate earnings impact.
• Channel execution for international growth: Oncotype’s international reach depends on exclusive distributors; underperformance by distributors could slow global revenue expansion.
• M&A and strategic optionality: The Abbott acquisition proposal (reported Nov 2025) changes risk/return calculus; if consummated, it restructures competitive dynamics and capital allocation for Exact’s tests.

For more granular relationship scoring and transaction-level evidence, visit https://nullexposure.com/.

Bottom line

Exact Sciences operates a payer‑centric, laboratory-services business where pension-grade revenue multiples depend on stable Medicare coverage, successful large‑payer contracting, and distributor execution outside the U.S. Investors should weigh existing payer concentration and the company’s distribution strategy against the potential strategic benefits and integration risk from acquisition discussions reported in the market. To review the underlying filings and relationship evidence used in this analysis, go to https://nullexposure.com/.